Supply Chain Intelligence

Galectin Therapeutics Inc. Supply Chain

GALT supply chain intelligence for Galectin Therapeutics Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

GALT ·Last updated 2026-07-30 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

5Suppliers
1Customers
3Debt Items
12Related Chains

Galectin Therapeutics Inc. Suppliers

TickerNameConfidenceEvidence
RICHARD-E-UIHLEIN RICHARD-E-UIHLEIN 92% The Lender shall provide the Company a line of credit of up to $10.00 million (the "Line of Credit") to finance the Company's working capital needs.
CONTRACT-RESEARCH-ORGANIZATIONS CONTRACT-RESEARCH-ORGANIZATIONS 90% Our current NAVIGATE clinical trial is being supported by third-party contract research organizations, or CROs, and other vendors.
CROS CROS 90% We accrue expenses for clinical trial activities performed by CROs based upon the estimated amount of work completed on each trial.
CONTRACT-VENDOR CONTRACT-VENDOR 85% The Company is involved in a dispute with a contract vendor for clinical trial management services provided outside of the United States.
GYRE Gyre Therapeutics, Inc. 72% Reciprocal relationship from GYRE graph: Reciprocal relationship from GALT graph: Reciprocal relationship from GYRE graph: Reciprocal relationship from GALT graph: Reciprocal relationship from GYRE g…

Galectin Therapeutics Inc. Customers

TickerNameConfidenceEvidence
MTVA MetaVia Inc. 72% Reciprocal relationship from MTVA graph: Reciprocal relationship from GALT graph: Reciprocal relationship from MTVA graph: Reciprocal relationship from GALT graph: Reciprocal relationship from MTVA g…

Galectin Therapeutics Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
GALT-DEBT-9710 Warrants outstanding: 500000 90% xbrl warrant detail from xbrl 2025-12-31.
GALT-DEBT-9711 Xbrl Convertible 90% xbrl convertible detail from xbrl 2021-04-16.
GALT-DEBT Debt stack $135.7M 90% Market cache reports total debt of $135.7M.

Galectin Therapeutics Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Galectin Therapeutics Inc..

Galectin Therapeutics Inc. Ownership

HolderNameConfidenceEvidence
GALT-OWNER-49-WEALTH-MANAGEMENT-LLC 49 WEALTH MANAGEMENT, LLC 90% 13F overlay lists 49 WEALTH MANAGEMENT, LLC as top holder; 1 tracked holders.

Galectin Therapeutics Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
GYRE Gyre Therapeutics, Inc. 100.00 1 ['supplier']
NVO Novo Nordisk A/S 50.00 2
VKTX Viking Therapeutics, Inc. 50.00 2
BMY Bristol-Myers Squibb Company 50.00 2
BMYMP Bristol-Myers Squibb Co 50.00 2
MDGL Madrigal Pharmaceuticals, Inc. 50.00 2
MRK Merck & Co., Inc. 50.00 2
LLY Eli Lilly and Company 50.00 2
AZN AstraZeneca PLC 50.00 2
IONS Ionis Pharmaceuticals, Inc. 50.00 2
GLMD Galmed Pharmaceuticals Ltd. 50.00 2
MTVA MetaVia Inc. 36.29 1 ['customer']
View GALT supply chain intel →

Explore the full interactive supply chain map for Galectin Therapeutics Inc..

Open GALT supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map